Senti Biosciences, Inc.
For the period ended Dec 9, 2025. Filed Dec 9, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Dec 9, 2025 · Filed Dec 9, 2025
Contents
EX-99.1 · About the Study
About the Study
The multinational, multicenter dose-finding study of SENTI-202 (NCT06325748) is comprised of an initial dose finding using a modified "3+3" study design to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RP2D) of SENTI-202 when administered after lymphodepleting chemotherapy (Part 1) followed by disease-specific expansion cohorts at the RP2D (Part 2).
The primary objectives are to evaluate safety, determine the MTD and RP2D, and assess efficacy in expansion cohorts using ELN 2022 consensus criteria for AML, with key secondary objectives including measurable residual disease assessment, pharmacokinetics, and pharmacodynamics using CyTOF on serial bone marrow samples. For more information visit clinicaltrials.gov
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.